MAP - Microba Life Sciences

[System]

Microba Life Sciences operates in the emerging US$4.89 billion gut microbiome sector impacting the chronic disease management market. The world leading technology developed by Microba is tapping into a growing body of research demonstrating that the gut microbiome plays a central role in health and disease which is driving demand for products and services to influence the gut microbiome and improve human health.

Microba is a commercial stage gut microbiome company that provides microbiome testing services to healthcare practitioners and consumers (via distributors) powered by the Company's world leading gut microbiome Analysis Platform. From these services, the company has built a proprietary microbiome Databank. The company is applying proprietary methods and artificial intelligence to the Databank to identify and develop multiple therapeutic candidates to address major chronic diseases.

Microba is executing on its strategy via its three complementary business pillars:

(a) Microbiome Services – Microba is an established leader in microbiome testing with over 20,000 microbiome test reports sold to date and market leading distribution partners including SYNLAB (EU), Genova Diagnostics (US), Psomagen (US), G42 (Middle East) and Metagenics (AU & NZ).

(b) Proprietary Databank – a large, unique, proprietary microbiome Databank comprising of over 1.2m microbial genomes. Microba’s Databank has enabled the Company to identify novel therapeutic leads not identified by others.

(c) Microbiome Therapeutics – Microba leverages its growing Databank through a repeatable Therapeutics Platform to develop novel microbiome therapeutics. Microba has established multiple therapeutic programs, including for Inflammatory Bowel Disease with a Phase 1b clinical trial planned to commence in late 2022.

Microba has recently signed a therapeutic development agreement with NYSE Listed Ginkgo Bioworks (NYSE: DNA) to address three autoimmune conditions. The Company's strategy is to partner or license our therapeutic assets with large pharmaceutical companies to leverage their capabilities in clinical trials and commercialisation

It is anticipated that MAP will list on the ASX during April 2022.

Microba Life Sciences | Precision microbiome science

Microba is at the forefront of microbiome science, pioneering health solutions that harness our deep understanding of the microbiome.

microba.com

 

[Dona Ferentes]

Listing date	5 April 2022 10:30 AM AEDT ##
Company contact details	Microba Life Sciences | Powering medical innovation - Microba Life Sciences Microba Life Sciences reveals new answers through precise analysis of the gut microbiome. We use the latest scientific technologies and evidence to provide comprehensive gut microbiome analysis. www.microba.com Ph: +61 1300 974 621
Principal Activities	Microba is a commercial stage company with leading technology for measuring the human gut microbiome which is: delivering gut microbiome testing services globally to consumers, clinicians, and researchers; and driving the discovery and development of novel therapeutics for major chronic diseases.
GICS industry group	TBA
Issue Price	AUD 0.45
Issue Type	Ordinary Fully Paid Shares
Security code	MAP
Capital to be Raised	$30,000,000
Expected offer close date	14 March 2022
Underwriter	Bell Potter Securities Limited and Canaccord Genuity (Australia) Limited (Joint Underwriters and Lead Managers)

 

[JohnDe]

SP starting to look stable.

 

[Dona Ferentes]

Stable? or has the horse bolted?

MAP never traded above IPO, and has more than halved. There is a Flicka of interest .

 

[JohnDe]

Stable? or has the horse bolted?

MAP never traded above IPO, and has more than halved. There is a Flicka of interest .

View attachment 149122

I’m not a holder, came across some information including present financials this morning and after reading the history & who’s now interested, I thought it looks in a better position than it was.

We’ll see during the remainder of the year.

 

[JohnDe]

Still not a holder, but I have been watching. Price keeps falling, with a big one today setting off my Watch notification.

 

[Country Lad]

@JohnDe this is an interesting one which I initially followed. Country Lass became interested in the gut biome issue some time ago and subsequent treatment overcame her problems.

There is no doubt about the science behind it, and no doubt is the reason Sonic Health, PVM and Thorney between them hold about 35% of the shares.

The problem as I see it is that the general population has no idea what it is about and consequently views gut microbiome as voodoo. GP doctors don’t regard it as a first line investigatory issue and look for all other possible causes of problems.

I think for these reasons it can’t gain any traction and will tread water until the real world catches up with the concept.

 

[JohnDe]

@JohnDe this is an interesting one which I initially followed. Country Lass became interested in the gut biome issue some time ago and subsequent treatment overcame her problems.

There is no doubt about the science behind it, and no doubt is the reason Sonic Health, PVM and Thorney between them hold about 35% of the shares.

The problem as I see it is that the general population has no idea what it is about and consequently views gut microbiome as voodoo. GP doctors don’t regard it as a first line investigatory issue and look for all other possible causes of problems.

I think for these reasons it can’t gain any traction and will tread water until the real world catches up with the concept.

I became interested because I understand the benefits of a good gut, but don't know enough about the company to invest, especially with the price dropping so radically. I wonder whether the floods had any issues with their offices.